Wednesday, June 16, 2010

SCRI Newsletter

Dear Readers,

It has been some time since a new entry has been placed on MedTruth, and this has been due to a new paper I have been writing for publication, "What Is Cancer?" This paper details a new causation for cancer and, based on this, new treatment options. More details will be forthcoming upon publication of this paper.

Meantime I thought it might be of interest to enter on MedTruth the Syracuse Cancer Research Intitute's latest semi-annual Newsletter.

Syracuse Cancer Research Institute

600 East Genesee Street

Syracuse, NY 13202

June 2010

Dear Friend,

Summer of 2010 is upon us and I am happy to inform you that the use of hydrazine sulfate for general cancer is beginning to spread rapidly worldwide. That is because more and more doctors are becoming acquainted with the controlled clinical trials of hydrazine sulfate in the medical literature, performed in accordance with international standards, and their specific results of efficacy and safety. And the reason this has happened is that the Internet has called special attention of the medical profession that these studies exist and should be consulted as part of any treatment-making decision.

I want to emphasize to each and every one of you that if you or a friend or loved one has cancer, the doctor should consider a course of hydrazine sulfate--whether or not other treatments are used, such as chemotherapy, radiation or some of the newer recombinant pharmaceuticals. Consider the statistics: those controlled clinical trials, done in conformity with the "generally accepted standards" rule (the Helsinki Declaration) demonstrate that for every million late-stage, unresponsive cancer patients given hydrazine sulfate, 500,000 will show measurable symptomatic improvements, 400,000 will have their tumors stop growing or regress and some will go on to long term (>10 years) survival. These are "factually terminal" patients. No studies have yet assessed earlier patients, who are known to respond more favorably to almost all drugs.

These hard-to-believe results are becoming known to many physicians, since they are now reportedly seeing these results in their own initial patients. And this is a worldwide phenomenon. Overseas Pharmsynthez, a pharmaceutical company, has been registering and marketing hydrazine sulfate as an approved drug in European countries and also in Canada, under the trade name Sehydrin. And in the United States the drug remains obtainable by a doctor's prescription.

It is really regretful that progress on this drug has moved so slowly. But for those who are regular readers of this Newsletter, the reasons for this are well known. Nevertheless, no matter what the past bottlenecks, hydrazine sulfate is now beginning to emerge globally as a drug capable of helping patients with common and recently diagnosed cancers, those who are advanced and those who literally have no further treatment options available.

I urge that if you or a loved one are diagnosed with cancer, that you consult your doctor about the advisability of including hydrazine sulfate in whatever treatment option may be considered. The actual statistics of permissibly performed studies indicate that doing so may well tip the scale of clinical response in your favor.

If we can be of help in providing you or your doctor with information or with clinical studies, please let us know. In the meantime we would appreciate your remembering us with a mid-year gift, as these gifts are the fuel that makes possible our continuing work.

With every best wish.


Joseph Gold, M.D.


P.S. Your gifts are tax-deductible to the extent allowed by law.

Visit us at:


Anonymous said...


Bob said...


Do you know if hydrazine sulfate is prescribable by doctors in the UK and is it available?
My daughter has pancreatic cancer which although was removed by a Whipple procedure has spread to her lungs. The cancer is slow but she also has cachexia which has caused severe weight loss and exhaustion, in your opinion, would she be able to take this drug safely?

Thank you,

AdamSmith said...

Please check Abstract

Hydrazine hepatotoxicity in vivo, as manifested by triglyceride accumulation, depletion of ATP and reduced glutathione (GSH) was shown to be dose related. The effect of pretreatment of rats with various inhibitors and inducers of cytochrome P450 on these dose-response relationships was investigated. Pretreatment with the inhibitor piperonyl butoxide increased triglyceride accumulation whereas pretreatment with the inducers phenobarbital and β-naphthoflavone (BNF) resulted in reduced triglyceride accumulation. Pretreatment with the inducers acetone and isoniazid also enhanced triglyceride accumulation. Only phenobarbital pretreatment also significantly reduced GSH and ATP depletion. A linear correlation was found between hepatic glutathione and ATP levels in non-pretreated animals given various doses of hydrazine. However, exponential relationships were found between hepatic triglycerides and both hepatic ATP and glutathione. The results suggest that i) the hepatotoxicity of hydrazine can be modulated by inducing or inhibiting particular isoenzymes of cytochrome P450, ii) ATP and GSH depletion may not be directly involved in the development of fatty liver.

Key words Hydrazine - Hepatotoxicity - Cytochrome P450 - Rat

Anonymous said...